NCT03524651View on ClinicalTrials.gov

Ferrous Acetyl-Aspartate Casein Formulation Evaluation Over Ferrous Sulfate in Iron Deficiency Anemia

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 2, 2018

Primary Completion Date

January 8, 2021

Study Completion Date

January 8, 2021

Conditions
Iron Deficiency Anemia
Interventions
DRUG

Ferrous Sulfate

Blisters of 10 capsules containing 150 mg of ferrous sulfate.

DRUG

Fe-ASP

Boxes of 10 vials of 15 ml containing 800 mg of Iron protein acetyl aspartate.

DRUG

Ferrous Sulfate

Boxes of 10 vials of 15 ml containing inactive ingredients of Omalin.

DRUG

Fe-ASP

Blisters of 10 capsules containing inactive ingredients of Microfer.

Trial Locations (3)

12462

Attikon University Hospital, Haidari/Athens

15127

Amalia Fleming Prefecture General Hospital of Melissia, Melíssia

115 27

General Hospital of Athens G. Gennimatas, Athens

All Listed Sponsors
collaborator

Attikon Hospital

OTHER

collaborator

Amalia Fleming Prefecture General Hospital of Melissia

UNKNOWN

collaborator

G.Gennimatas General Hospital

OTHER

lead

Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.

INDUSTRY

NCT03524651 - Ferrous Acetyl-Aspartate Casein Formulation Evaluation Over Ferrous Sulfate in Iron Deficiency Anemia | Biotech Hunter | Biotech Hunter